AU2003222326A1 - Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases - Google Patents

Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases

Info

Publication number
AU2003222326A1
AU2003222326A1 AU2003222326A AU2003222326A AU2003222326A1 AU 2003222326 A1 AU2003222326 A1 AU 2003222326A1 AU 2003222326 A AU2003222326 A AU 2003222326A AU 2003222326 A AU2003222326 A AU 2003222326A AU 2003222326 A1 AU2003222326 A1 AU 2003222326A1
Authority
AU
Australia
Prior art keywords
composition
nervous system
central nervous
brain barrier
blood brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222326A
Inventor
Pierre Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Publication of AU2003222326A1 publication Critical patent/AU2003222326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003222326A 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases Abandoned AU2003222326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0200259A FR2834465A1 (en) 2002-01-10 2002-01-10 COMPOSITIONS FOR THE VECTORIZATION OF OLIGONUCLEOTIDES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
FR02/00259 2002-01-10
PCT/FR2003/000074 WO2003059394A1 (en) 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases

Publications (1)

Publication Number Publication Date
AU2003222326A1 true AU2003222326A1 (en) 2003-07-30

Family

ID=8871225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222326A Abandoned AU2003222326A1 (en) 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases

Country Status (3)

Country Link
AU (1) AU2003222326A1 (en)
FR (1) FR2834465A1 (en)
WO (1) WO2003059394A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968662B1 (en) 2010-12-10 2013-11-22 Roussy Inst Gustave NOVEL PRE-ACTIVE OXAZAPHOSPHORINE DERIVATIVES, USE AND METHOD OF PREPARATION
AU2017312116A1 (en) 2016-08-17 2019-03-07 Solstice Biologics, Ltd. Polynucleotide constructs
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc Peptide-enhanced cationic lipid transfections
AU5590999A (en) * 1998-09-01 2000-03-21 Trustees Of The University Of Pennsylvania, The Peptide scaffolds for transfer of molecules into eukaryotic cells
FR2818981A1 (en) * 2001-01-03 2002-07-05 Synt Em AMPHIPATHIC PEPTIDES AND THEIR USE FOR THE TRANSFER OF SUBSTANCES OF INTEREST TO CELLS

Also Published As

Publication number Publication date
WO2003059394A3 (en) 2004-03-11
WO2003059394A1 (en) 2003-07-24
FR2834465A1 (en) 2003-07-11

Similar Documents

Publication Publication Date Title
HK1079993A1 (en) Drugs for treating vascular diseases
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
EP1535971A4 (en) Treated pigment, use thereof, and compound for pigment treatment
PL1656346T3 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
ZA200107315B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury.
HK1064669A1 (en) Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain.
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
EP1676132A4 (en) System and method for the treatment of cancer, including cancers of the central nervous system
AU2003229835A8 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
EP1624786A4 (en) Methods for the treatment and prevention of diseases of biological conduits
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
AU2003222326A1 (en) Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases
GB2441078B (en) Implantable network biosensor and system for diagnosis and therapy
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase